Daily Ards Research Analysis
Across pediatric and critical care respiratory research, a multicenter analysis identified plasma soluble ICAM-1 as a central biomarker linked to worse outcomes in pediatric ARDS/acute respiratory failure. A retrospective cohort suggests day-7 respiratory and ECMO parameters can inform prognostication during prolonged V-V ECMO. A small randomized trial found a reprocessed bubble CPAP system did not increase neonatal sepsis, supporting scalable access to respiratory support.
Summary
Across pediatric and critical care respiratory research, a multicenter analysis identified plasma soluble ICAM-1 as a central biomarker linked to worse outcomes in pediatric ARDS/acute respiratory failure. A retrospective cohort suggests day-7 respiratory and ECMO parameters can inform prognostication during prolonged V-V ECMO. A small randomized trial found a reprocessed bubble CPAP system did not increase neonatal sepsis, supporting scalable access to respiratory support.
Research Themes
- Biomarker-driven phenotyping in pediatric ARDS
- Prognostication during prolonged V-V ECMO support
- Safe, scalable neonatal respiratory support technologies
Selected Articles
1. Plasma Soluble Intercellular Adhesion Molecule-1 Has a Central Role in Biomarker Network Analysis and Is Associated With Poor Outcomes in Two Distinct Pediatric Cohorts of Acute Respiratory Distress Syndrome and Acute Respiratory Failure.
In two multicenter pediatric cohorts (n=465), higher plasma sICAM-1 measured within 72 hours of diagnosis was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days. Network analysis across 33 biomarkers identified sICAM-1 as a central hub alongside TIMP-1, TNFR1, and IL-8, underscoring endothelial/leukocyte trafficking pathways in ARDS pathophysiology.
Impact: This work integrates robust multicenter data with biomarker network analysis to elevate sICAM-1 from a prognostic marker to a central node in pediatric ARDS/ARF pathobiology. It provides a mechanistic anchor for future risk stratification and targeted trials.
Clinical Implications: Early sICAM-1 measurement could inform risk stratification and ventilatory/adjunctive therapy intensity in pediatric ARDS/ARF. It also supports development of multiplex biomarker panels capturing endothelial and inflammatory axes.
Key Findings
- Higher plasma sICAM-1 within 72 hours was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days in both cohorts (p<0.05).
- Network analysis (sICAM-1 plus 32 biomarkers) identified sICAM-1 (composite centrality 0.74) as a hub alongside TIMP-1 (0.99), TNFR1 (0.83), and IL-8 (0.74).
- Cohorts included 214 ARDS (PALI) and 251 ARF (CAF-PINT) patients, with in-hospital mortality of 18% and 14%, respectively; baseline median oxygenation index ratios were 10 and 8.5.
Methodological Strengths
- Secondary analysis of two large, multicenter prospective cohorts with standardized early biomarker sampling (within 72 hours).
- Comprehensive biomarker network analysis contextualizing sICAM-1 within endothelial and inflammatory pathways.
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded.
- Cohorts span 2008–2016; temporal changes in ARDS care may affect generalizability.
Future Directions: Validate sICAM-1 thresholds in contemporary cohorts, assess additive value in multivariable prognostic models, and explore ICAM-1–targeted or endothelial-stabilizing interventions.
OBJECTIVES: Intercellular adhesion molecule-1 (ICAM-1) is a glycoprotein expressed on immune, endothelial, and epithelial cells. In the setting of inflammation, it becomes upregulated and spliced into a soluble form (soluble ICAM-1 [sICAM-1]). This study examined the association of sICAM-1 with clinical outcomes in two large pediatric cohorts with acute respiratory distress syndrome (ARDS) and acute respiratory failure (ARF) and examined the relationships between sICAM-1 and other protein biomarkers utilizing network analysis to contextualize its role in ARDS pathophysiology. DESIGN: Secondary analysis of prospective cohort studies. SETTING: Multicenter PICUs. PATIENTS OR SUBJECTS: Critically ill children with ARDS (Pediatric Acute Lung Injury [PALI], 2008-2014) and ARF (Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial [CAF-PINT], 2012-2016). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: sICAM-1 levels were measured from plasma collected within 72 hours of diagnosis. The primary outcome was in-hospital mortality, and secondary outcomes included multiple organ dysfunction and ventilator-free days. We constructed a biomarker correlation-based network that included sICAM-1 and 32 plasma biomarkers reflective of inflammation, endothelial and epithelial injury, and extracellular matrix degradation. Key biomarkers with centrality metrics in the top 10% (≥ 90th percentile) were defined as critical hubs within the network. The study included 214 children from PALI and 251 from CAF-PINT. In-hospital mortality was 18% and 14%, respectively. Baseline median oxygenation index ratios were 10 (interquartile range [IQR], 5.6-19.7) and 8.5 (IQR, 3.5-17.7). Higher plasma sICAM-1 was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days in each of the two cohorts (all p < 0.05). Tissue inhibitor of metalloproteinase-1 (composite centrality, 0.99), tumor necrosis factor receptor-1 (0.83), sICAM-1 (0.74), and interleukin-8 (0.74) were identified as network hubs. CONCLUSIONS: Elevated sICAM-1 levels were associated with poor outcomes in two separate cohorts of ARDS and ARF patients. Network analysis revealed sICAM-1 as a central hub, characterized by high centrality metrics. These findings underscore the multifaceted role of sICAM-1 in leukocyte transmigration, inflammation, and endothelial dysfunction and highlight its critical role in ARDS pathophysiology.
2. Prognosis After Seven Days of Veno-Venous Extracorporeal Membrane Oxygenation Support.
In a single-center cohort of 299 V-V ECMO patients (72.2% pneumonia), overall hospital survival was 44.8%. Among those still on ECMO at day 7 (n=182), survival was 45.1%, and respiratory/ECMO parameters above a predefined favorability margin strongly correlated with survival, highlighting day 7 as a pragmatic prognostic checkpoint.
Impact: Identifies a clinically actionable time point and parameter-based framework to guide prognostication during prolonged V-V ECMO, informing communication and decision-making.
Clinical Implications: Day-7 reassessment using respiratory and ECMO parameters may stratify survival likelihood, supporting goals-of-care discussions and resource allocation during prolonged ECMO.
Key Findings
- Among 299 V-V ECMO patients, overall hospital survival was 44.8%; pneumonia accounted for 72.2% of indications.
- On day 7, 60.9% (182/299) remained on ECMO with a hospital survival rate of 45.1%.
- Respiratory and ECMO parameters above a predefined favorability margin strongly correlated with survival; survival was rare when all predictors were below the margin.
Methodological Strengths
- Relatively large ECMO cohort with clear primary endpoint (hospital survival).
- Operationalizes a pragmatic prognostic threshold (favorability margin) at a clinically meaningful time point (day 7).
Limitations
- Single-center retrospective design limits generalizability and causal inference.
- Incomplete abstract details on specific parameters and potential confounder adjustments.
Future Directions: Prospective multicenter validation of day-7 prognostic parameters and integration with dynamic risk models and shared decision-making tools.
BACKGROUND: Prognostication in patients receiving veno-venous extracorporeal membrane oxygenation (V-V ECMO) remains challenging, particularly during prolonged support. Accurate prognostic indicators are essential for patients, caregivers, and clinicians. This study evaluates outcomes in patients supported with V-V ECMO for at least seven days. METHODS: We conducted a single-center retrospective cohort study of patients cannulated for V-V ECMO due to respiratory failure. The primary endpoint was hospital survival. The subgroup of patients still on V-V ECMO on day 7, stratified by respirator and ECMO parameters, was analyzed with respect to predictors of the primary outcome. A survival favorability margin was defined as the bound of the hospital survivors' 95% confidence interval closest to the non-survivor median. RESULTS: Among 299 patients treated with V-V ECMO (median age 55 years, 66.9% male), hospital survival was 44.8%. Pneumonia was the primary cause of respiratory failure in 216 patients (72.2%). By day 7, 182/299 patients (60.9%) remained on V-V ECMO, with a hospital survival rate of 45.1%. Three respiratory parameters (ventilator FiO CONCLUSION: Among patients still on V-V ECMO on day seven, respiratory and ECMO parameters above the favorability margin correlated strongly with hospital survival. Survival was rare in patients with all predictors below the favorability margin. Day seven could provide a useful, though not definitive, time point for prognostication based on respiratory and ECMO parameters.
3. Evaluation of a novel reprocessed bCPAP system on sepsis rates among preterm neonates with respiratory distress: a randomized controlled trial.
In a randomized trial of 75 neonates with respiratory distress, use of a reprocessed bCPAP system did not increase neonatal sepsis, with no significant differences in death, escalation of care, or composite outcomes. The findings support safe reuse-oriented device strategies to expand CPAP access.
Impact: Provides randomized evidence addressing safety of a reuse-designed bCPAP system, a practical barrier to CPAP access in resource-limited settings.
Clinical Implications: Reprocessed bCPAP systems may be deployed without increasing sepsis risk, supporting scale-up of neonatal respiratory support where access to disposables is limited.
Key Findings
- Seventy-five neonates were randomized to two CPAP arms; no increase in neonatal sepsis with the reprocessed bCPAP system.
- No significant differences in death (5 vs 4), escalation of care (10 vs 9), or composite outcome (OR 0.84; 95% CI 0.30–2.35).
- Trial registered at ClinicalTrials.gov (NCT06082674), supporting methodological transparency.
Methodological Strengths
- Randomized controlled design with prespecified safety outcomes.
- Addresses a pragmatic implementation question relevant to global neonatal care.
Limitations
- Small sample size limits power to detect modest differences in sepsis rates.
- Abstract provides limited methodological detail (e.g., blinding, adjudication, and full outcome definitions).
Future Directions: Larger, multicenter non-inferiority trials with microbiologically adjudicated sepsis, cost-effectiveness analyses, and durability assessments in real-world LMIC settings.
INTRODUCTION: Bubble CPAP (bCPAP) is highly effective in the treatment of respiratory distress syndrome of prematurity and other causes of newborn respiratory insufficiency. To overcome barriers to bCPAP access a novel system was developed that is designed to be cleaned, disinfected, and reused. This study evaluated whether use of reprocessed bCPAP systems increases the rate of sepsis in neonates. METHODS: A RESULTS: Seventy-five neonates were randomized to the two CPAP treatment arms. No significant differences in death (5 vs. 4), escalation of care (10 vs. 9), and the composite outcome (OR = 0.84; 95% CI: 0.30-2.35, DISCUSSION: Use of a reprocessed bCPAP system designed to increase global access to CPAP did not increase rates of neonatal sepsis. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier, (NCT06082674).